Pharmesis International Ltd. announced audited consolidated earnings results for the year ended December 31, 2017. For the year, the company reported revenue of RMB 69,727,000 against RMB 68,839,000 a year ago, representing a growth of 1.3%. This was mainly attributable to higher sales from non-prescribed drugs segment brought on by increasing demand for ErDing granules, partially offset by lower sales from prescribed drugs segment. Revenue growth was partly affected by the downtime in manufacturing arising from the preparation of manufacturing revised product, sugarless ErDing granules which will replace the existing ErDing granules with sugar. Loss before tax was RMB 1,286,000 against RMB 4,352,000 a year ago. Loss attributable to equity holders of the company was RMB 2,477,000 or 10.8 cents per basic and diluted share against RMB 4,640,000 or 20.2 cents per basic and diluted share a year ago. Net cash flows from operating activities were RMB 2,679,000 against net cash flows used in operating activities of RMB 31,418,000 a year ago. Acquisition of property, plant and equipment was RMB 1,392,000 against RMB 868,000 a year ago.